Cargando…

The CD105:CD106 microparticle ratio is CD106 dominant in polycystic ovary syndrome compared to type 2 diabetes and healthy subjects

BACKGROUND: A retrospective analysis was carried out from patients and controls during the past 5 years from a series of studies investigating endothelial microparticles (MP). METHODS: In total, 319 samples from 207 individuals were included in this analysis, from patients with type 2 diabetes (T2D,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al-Qaissi, Ahmed, Alqarni, Saeed, Javed, Zeeshan, Atkin, Stephen L., Sathyapalan, Thozhukat, Vince, Rebecca V., Madden, Leigh A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6838044/ https://www.ncbi.nlm.nih.gov/pubmed/31456040 http://dx.doi.org/10.1007/s12020-019-02059-9

Ejemplares similares

The effects of empagliflozin vs metformin on endothelial microparticles in overweight/obese women with polycystic ovary syndrome
por: Javed, Zeeshan, et al.
Publicado: (2020)

Salivary testosterone measurement in women with and without polycystic ovary syndrome
por: Sathyapalan, Thozhukat, et al.
Publicado: (2017)

Salivary and serum androgens with anti-Müllerian hormone measurement for the diagnosis of polycystic ovary syndrome
por: Sathyapalan, Thozhukat, et al.
Publicado: (2018)

Human epithelial ovarian cancer cells expressing CD105, CD44 and CD106 surface markers exhibit increased invasive capacity and drug resistance
por: Zhang, Jin, et al.
Publicado: (2019)

Mediators of Inflammation in Polycystic Ovary Syndrome in Relation to Adiposity
por: Sathyapalan, Thozhukat, et al.
Publicado: (2010)

Nuclear moments and charge radii of $^{105,106}$In
por: Lochmann, H, et al.
Publicado: (1985)

Pharmacological Treatment of Obesity in Patients with Polycystic Ovary Syndrome
por: Kahal, Hassan, et al.
Publicado: (2011)

Search for first 0 excited states in /sup 108/Cd and /sup 106/Cd
por: Roussière, B, et al.
Publicado: (1981)

High spin proton and neutron intruder configurations in $^{106}$Cd
por: Regan, P H, et al.
Publicado: (1994)

Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome
por: Alalami, Huda, et al.
Publicado: (2018)

Circulating Endothelial Microparticles Reduce in Concentration Following an Exercise Programme in Women With Polycystic Ovary Syndrome
por: Kirk, Richard J., et al.
Publicado: (2019)

Components of the Complement Cascade Differ in Polycystic Ovary Syndrome
por: Butler, Alexandra E., et al.
Publicado: (2022)

The Effect of Exenatide on Cardiovascular Risk Markers in Women With Polycystic Ovary Syndrome
por: Dawson, Alison J., et al.
Publicado: (2019)

A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome
por: Abdalla, Mohammed Altigani, et al.
Publicado: (2020)

Pregnancy in polycystic ovary syndrome
por: Kamalanathan, Sadishkumar, et al.
Publicado: (2013)

ODP141 Complement Activation and Homeostasis Works Primarily Through the Alternative Pathway in Polycystic Ovary Syndrome
por: Atkin, Stephen, et al.
Publicado: (2022)

COVID-19 biomarkers for severity mapped to polycystic ovary syndrome
por: Moin, Abu Saleh Md, et al.
Publicado: (2020)

The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome
por: Sathyapalan, Thozhukat, et al.
Publicado: (2017)

CD36 Participates in PrP(106–126)-Induced Activation of Microglia
por: Kouadir, Mohammed, et al.
Publicado: (2012)

Correction to: COVID-19 biomarkers for severity mapped to polycystic ovary syndrome
por: Moin, Abu Saleh Md, et al.
Publicado: (2021)

Complement Dysregulation in Obese Versus Nonobese Polycystic Ovary Syndrome Patients
por: Butler, Alexandra E., et al.
Publicado: (2023)

The Association of the Polychlorinated Biphenyl Class of Endocrine Disruptors With Polycystic Ovary Syndrome and Thyroid Dysfunction
por: Brennan, Edwina, et al.
Publicado: (2021)

Erratum. Therapeutic Inertia Is a Problem for All of Us. Clinical Diabetes 2019;37:105–106 (DOI: 10.2337/cd19-0009)
por: Brunton, Stephen A.
Publicado: (2020)

The potential role of incretin-based therapies for polycystic ovary syndrome: a narrative review of the current evidence
por: Abdalla, Mohammed Altigani, et al.
Publicado: (2021)

A Randomized, Controlled Trial of Vitamin D Supplementation on Cardiovascular Risk Factors, Hormones, and Liver Markers in Women with Polycystic Ovary Syndrome
por: Javed, Zeeshan, et al.
Publicado: (2019)

Correction: CD36 Participates in PrP(106–126)-Induced Activation of Microglia
por: Kouadir, Mohammed, et al.
Publicado: (2012)

CD106 Identifies a Subpopulation of Mesenchymal Stem Cells with Unique Immunomodulatory Properties
por: Yang, Zhou Xin, et al.
Publicado: (2013)

The Effect of Atorvastatin (and Subsequent Metformin) on Adipose Tissue Acylation-Stimulatory-Protein Concentration and Inflammatory Biomarkers in Overweight/Obese Women With Polycystic Ovary Syndrome
por: Sathyapalan, Thozhukat, et al.
Publicado: (2019)

Biomarkers of COVID-19 severity may not serve patients with polycystic ovary syndrome
por: Moin, Abu Saleh Md, et al.
Publicado: (2021)

The relationship of soluble neuropilin-1 to severe COVID-19 risk factors in polycystic ovary syndrome
por: Moin, Abu Saleh Md, et al.
Publicado: (2021)

Metabolic consequences of obesity on the hypercoagulable state of polycystic ovary syndrome
por: Moin, Abu Saleh Md, et al.
Publicado: (2021)

Vitamin D association with coagulation factors in polycystic ovary syndrome is dependent upon body mass index
por: Moin, Abu Saleh Md, et al.
Publicado: (2021)

Renin-Angiotensin System overactivation in polycystic ovary syndrome, a risk for SARS-CoV-2 infection?
por: Moin, Abu Saleh Md, et al.
Publicado: (2020)

Vitamin D Association With Macrophage-Derived Cytokines in Polycystic Ovary Syndrome: An Enhanced Risk of COVID-19 Infection?
por: Moin, Abu Saleh Md, et al.
Publicado: (2021)

Inflammatory Markers in Non-Obese Women with Polycystic Ovary Syndrome Are Not Elevated and Show No Correlation with Vitamin D Metabolites
por: Moin, Abu Saleh Md, et al.
Publicado: (2022)

Serum polychlorinated biphenyl levels and circulating miRNAs in non-obese women with and without polycystic ovary syndrome
por: Brennan, Edwina, et al.
Publicado: (2023)

Oxidative Stress Markers and Heat Shock Proteins in Non-Obese Women with Polycystic Ovary Syndrome Are Not Elevated and Show No Correlation with Vitamin D
por: Nandakumar, Manjula, et al.
Publicado: (2023)

SAT366 Expression of Amyloid-related Proteins Associated With Dementia in Polycystic Ovary Syndrome Compared to a Control Population
por: Butler, Alexandra E, et al.
Publicado: (2023)

The Effect of Free Androgen Index on the Quality of Life of Women With Polycystic Ovary Syndrome: A Cross-Sectional Study
por: Abdalla, Mohammed Altigani, et al.
Publicado: (2021)

HDL-Associated Proteins in Subjects with Polycystic Ovary Syndrome: A Proteomic Study
por: Butler, Alexandra E., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_b1m3ale8na2bb9pgloecbsi3ng